Oryzon Genomics S.A. (BME:ORY)
2.580
-0.035 (-1.34%)
Aug 12, 2025, 5:35 PM CET
Oryzon Genomics Revenue
Oryzon Genomics had revenue of 4.22M EUR in the quarter ending June 30, 2025, with 2.73% growth. This brings the company's revenue in the last twelve months to 7.47M, down -30.93% year-over-year. In the year 2024, Oryzon Genomics had annual revenue of 7.36M, down -48.15%.
Revenue (ttm)
7.47M
Revenue Growth
-30.93%
P/S Ratio
27.13
Revenue / Employee
158.96K
Employees
47
Market Cap
202.70M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.36M | -6.83M | -48.15% |
Dec 31, 2023 | 14.19M | -1.51M | -9.60% |
Dec 31, 2022 | 15.70M | 5.08M | 47.88% |
Dec 31, 2021 | 10.62M | 1.09M | 11.49% |
Dec 31, 2020 | 9.52M | -756.51K | -7.36% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Grifols | 7.45B |
Laboratorios Farmaceuticos Rovi | 749.00M |
Almirall | 1.05B |
Pharma Mar | 189.27M |
Faes Farma | 543.77M |
Clínica Baviera | 288.92M |
Laboratorio Reig Jofre | 336.02M |
Atrys Health | 218.10M |
Oryzon Genomics News
- 13 days ago - ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025 - Benzinga
- 3 months ago - Oryzon Genomics S.A. GAAP EPS of -$0.03 - Seeking Alpha
- 5 months ago - Oryzon Genomics S.A. GAAP EPS of -$0.02 - Seeking Alpha
- 7 months ago - ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting - Benzinga